---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-130812"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:28:54.320823+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h

## Summary
- Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.
- Cohort 3 dose will be approximately double the Cohort 2 dose; enrollment ongoing.
- Cohort 1 PK/PD data consistent with preclinical and Phase 0; 66% miR-10b inhibition at 24h post-infusion.
- Plasma concentration of TTX-MC138 in humans exceeded nonclinical levels, suggesting favorable PK.
- Several patients from Cohorts 1 and 2 remain on study for continued treatment.

## SEC filing metadata
- accession: 0001104659-24-130812
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924130812/0001104659-24-130812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924130812/tm2431511d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-130812
- JSON: https://secwatch.observer/filing/0001104659-24-130812.json
- Plain text: https://secwatch.observer/filing/0001104659-24-130812.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.